Stem Cell Therapy Market, By Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Others), By Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, Others), By End User (Hospitals, Cell Banks , Academic and Research Institutes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024

Code : CMI2848

Pages :153

Formats :

Excel and PDF

Industry : Biotechnology

Key Developments

In August 2023, Aspen Neuroscience, a pharmaceutical company, announced that it had received an approval from U.S. Food and Drug Administration to launch a clinical trial of ANPD001, an experimental stem cell therapy designed to replace the nerve cells that are lost in Parkinson’s disease
In October 2022, Cedars-Sinai Medical Center, announced that it had been awarded a five-year, USD 8 million grant from California’s stem cell agency to launch an innovative new clinic that will expand patients’ access to stem cell and gene therapies, increase research and training in regenerative medicine, foster greater collaboration with eight similar clinics across the state and help educate the public about stem cell and related therapies
In January 2022, Century Therapeutics, a biotechnology company, and Bristol Myers Squibb Company, a healthcare company, announced a research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cells (iPSC) derived, engineered natural killer cell (iNK) and / or T cell (iT) programs for hematologic malignancies and solid tumors
In June 2020, Shanghai Cell Therapy Group (SHCell), a provider of cellular diagnosis center combining cellular research and treatment services, announced that it had entered into a research collaborative project with the University of Southern California (USC) to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.